Business Context and Reporting Period
This Form 8-K was filed by Scilex Holding Company on July 22, 2025. The report details a material definitive agreement involving the Company's wholly owned subsidiary, Semnur Pharmaceuticals, Inc. ("Semnur"). Semnur is in the process of a business combination with Denali Capital Acquisition Corp. ("Denali") via a merger with Denali Merger Sub Inc.
Key Financial Metrics
This filing is a current report regarding a corporate transaction and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics for Scilex Holding Company or Semnur. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
On July 22, 2025, Semnur entered into Amendment No. 2 to the existing Merger Agreement with Denali. The primary material changes include:
- Modification of the definitions for "Exchange Ratio" and "Merger Consideration."
- Facilitation of the issuance of additional Semnur common stock prior to the closing of the Business Combination.
- Authorization for stock issuance to support potential private placement financing or compensation for advisors and service providers.
- Maintenance of the 1.25-to-1 exchange ratio despite the potential issuance of additional shares.
Guidance, Outlook, and Risks
Outlook and Management Commentary: The Company anticipates the consummation of the Business Combination, subject to shareholder approval and other conditions. Denali has filed a Registration Statement on Form S-4, and a definitive proxy statement/final prospectus will be mailed to Denali shareholders for an extraordinary general meeting.
Risks and Contingencies: The filing outlines significant risks that could prevent the transaction from closing or alter its terms, including:
- Failure to obtain necessary shareholder approvals from Semnur or Denali.
- Inability to secure required financing.
- High volume of redemption requests by Denali shareholders.
- Failure to maintain Nasdaq or OTC Markets listing post-transaction.
- Disruption of current operations and difficulty in integrating businesses.
- Receipt of unsolicited offers or legal proceedings.
Unusual Items: The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially from expectations due to various uncertainties.
Investor Verification Checklist
- Review the definitive proxy statement/final prospectus filed by Denali on Form S-4 for complete transaction details.
- Verify the specific terms of Amendment No. 2 to the Merger Agreement (Exhibit 2.1) regarding the mechanics of the exchange ratio adjustment.
- Monitor the status of shareholder approval votes for both Semnur and Denali.
- Assess the likelihood of successful private placement financing to support the transaction.
- Check for any updates regarding the listing status of the combined entity on Nasdaq.